Lee Ji Hyun, Kay Chul Seung, Maeng Lee So, Oh Se Jeong, Lee An Hi, Lee Jeong Deuk, Han Chi Wha, Cho Sang Hyun
Department of Dermatology, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Ann Dermatol. 2009 Nov;21(4):358-63. doi: 10.5021/ad.2009.21.4.358. Epub 2009 Nov 30.
Radiation therapy (RT) including tomotherapy has been widely used to treat primary tumors, as well as to alleviate the symptoms of metastatic cancers.
The primary purpose of this study was to examine the characteristics of the clinical features and pathophysiological mechanisms associated with acute radiation dermatitis in cancer patients that received tomotherapy, and compare the results to patients treated by conventional radiation therapy.
The study population consisted of 11 patients that were referred to the dermatology department because of radiation dermatitis after receiving tomotherapy; all patients were evaluated for clinical severity. The patients were assessed and identified using the National Cancer Institute Common Toxicity Criteria version (CTC) 3.0. We performed biopsies of the skin lesions that were examined for apoptosis using the terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labelling (TUNEL) assay and stained immunohistochemically with monoclonal antibodies to CD8, CD4 and TGF-beta. As a positive control, patients with radiation dermatitis treated with conventional radiation therapy were also studied.
THE RESULTS OF THE CLINICAL FEATURES OF THE SKIN OF TOMOTHERAPY PATIENTS WERE THE FOLLOWING: grade 1 (36%), grade 2 (55%) and other changes (9%). Among the population that had skin lesions due to acute radiation dermatitis, the mean number of positive cells per high power field (HPF) was the following: there were 30.50+/-7.50 TUNEL-positive cells, 34.60+/-12.50 CD8+ T cells, 5.19+/-3.17 CD4+ T cells and 9.95+/-1.33 TGF-beta positive cells measured per HPF. The mean number of positive cells per HPF for the patients that received conventional radiation therapy was: TUNLEL-positive cells in 7.5+/-1.64, CD8-, CD4- and TGF-beta-positive cells in 12.50+/-3.73, 3.16+/-1.47, 6.50+/-1.97.
We found that the number of TUNEL-positive cells and CD8+ T cells were higher in the lesions of patients receiving tomotherapy compared to the lesions of the patients receiving conventional radiation therapy. These findings suggest that tomotherapy without dose modification may cause significantly more severe forms of radiation dermatitis by apoptosis and cytotoxic immune responses than conventional radiation therapy.
包括断层放射治疗在内的放射治疗已广泛用于治疗原发性肿瘤以及缓解转移性癌症的症状。
本研究的主要目的是检查接受断层放射治疗的癌症患者急性放射性皮炎的临床特征和病理生理机制,并将结果与接受传统放射治疗的患者进行比较。
研究人群包括11例因接受断层放射治疗后出现放射性皮炎而转诊至皮肤科的患者;所有患者均评估了临床严重程度。使用美国国立癌症研究所通用毒性标准第3.0版(CTC)对患者进行评估和鉴定。我们对皮肤病变进行活检,使用末端脱氧核苷酸转移酶介导的脱氧尿苷三磷酸缺口末端标记(TUNEL)法检测细胞凋亡,并使用抗CD8、CD4和转化生长因子-β(TGF-β)单克隆抗体进行免疫组织化学染色。作为阳性对照,也对接受传统放射治疗的放射性皮炎患者进行了研究。
断层放射治疗患者皮肤临床特征的结果如下:1级(36%),2级(55%)和其他变化(9%)。在因急性放射性皮炎出现皮肤病变的人群中,每高倍视野(HPF)阳性细胞的平均数如下:每HPF检测到30.50±7.50个TUNEL阳性细胞、34.60±12.50个CD8 + T细胞、5.19±3.17个CD4 + T细胞和9.95±1.33个TGF-β阳性细胞。接受传统放射治疗患者每HPF阳性细胞的平均数为:TUNEL阳性细胞7.5±1.64个,CD8、CD4和TGF-β阳性细胞分别为12.50±3.73个、3.16±1.47个、6.50±1.97个。
我们发现,与接受传统放射治疗的患者病变相比,接受断层放射治疗的患者病变中TUNEL阳性细胞和CD8 + T细胞的数量更高。这些发现表明,在不调整剂量的情况下,断层放射治疗可能比传统放射治疗通过细胞凋亡和细胞毒性免疫反应导致更严重形式的放射性皮炎。